Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting - Its impact on clinical practice

Goel, G and Sun, W (2015) Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting - Its impact on clinical practice. Journal of Hematology and Oncology, 8 (1).

Preview	PDF Published Version Available under License : See the attached license file. Download (362kB) | Preview
	Plain Text (licence) Available under License : See the attached license file. Download (1kB)

Abstract

The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Article
Status:	Published
Creators/Authors:	Creators Email Pitt Username ORCID Goel, G Sun, W wes45@pitt.edu WES45
Date:	28 July 2015
Date Type:	Publication
Journal or Publication Title:	Journal of Hematology and Oncology
Volume:	8
Number:	1
DOI or Unique Handle:	10.1186/s13045-015-0183-8
Refereed:	Yes
Date Deposited:	17 Aug 2016 13:47
Last Modified:	03 Apr 2021 10:55
URI:	http://d-scholarship.pitt.edu/id/eprint/29225

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

---

Actions (login required)

View Item